Korea Q4 Roundup: GC’s IVIG US Approval, SK Biopharm Turns Around

Hanmi May Face Shareholders' Vote

 
• By Jung Won Shin
  
earnings
Yuhan's Lazertinib Reimbursed, Approved As 1L NSCLC Therapy • Source: Shutterstock

More from South Korea

More from Focus On Asia